about
Selective use of sorafenib in the treatment of thyroid cancerMolecular Targeted Therapies of Aggressive Thyroid CancerNovel approaches in anaplastic thyroid cancer therapyLaser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.The variable phenotype and low-risk nature of RAS-positive thyroid nodules.RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumorsBRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells.Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodulesMolecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2.Diagnostic Value of RAS Mutations in Indeterminate Thyroid Nodules.Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.Values of molecular markers in the differential diagnosis of thyroid abnormalities.A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma.Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer.Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.Integrating omics data and protein interaction networks to prioritize driver genes in cancer.Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles.Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.ATF1 and RAS in exosomes are potential clinical diagnostic markers for cervical cancer.Utility of intraoperative frozen sections for thyroid nodules with prior fine needle aspiration cytology diagnosis.Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.Sorafenib in the treatment of thyroid cancer.Transcriptional targeting of oncogene addiction in medullary thyroid cancerMolecular testing in the diagnosis of differentiated thyroid carcinomas
P2860
Q26752891-98A689F4-AA6F-419B-A27E-0FCEB721003CQ26774734-B62DE096-F657-4950-9DDE-20636B7DD9C6Q34458018-C8ED7ED5-D34F-4BA7-93F1-0C523D445065Q35501424-E0505502-9BB9-48D1-A448-A0F6FC3D0388Q35740151-35121F72-4ECC-4ED2-A5E5-8D2C7229C617Q35858147-326963A3-9E01-4EE6-9A68-3EC82AE3C365Q35906046-9BB81FED-333F-46AD-9691-D464931810BCQ35951601-36534949-BCA7-4CF6-B61D-BB0B0263AE8EQ36360429-30E2A1A3-E0EC-474C-A8F0-9FF750E46D53Q36452225-0718A130-DFA4-4B54-A7C9-E732EF8C9010Q36850544-AFC7186A-BCB5-4142-99A9-51576069C1E4Q37591876-8F3BF1CB-C113-4565-85A3-0A2F9E87D613Q38243095-39ED3103-AEED-420F-BF13-74EB5F636215Q38823954-1948DFC0-56AC-4E5F-887E-0E29D6AD22E2Q39002421-84C16A45-8DC9-454B-BD5B-3993CECF1492Q39002659-6C24EE3D-5570-4017-BD4E-9E42E0D58DDBQ39040663-EB7D7121-9870-468D-A98D-0EF75B4CFB88Q39051174-46B86BA0-4B7E-4B67-961F-A8502C2CD14CQ39064503-ED652301-83C1-4F57-A452-E17D7B585EA0Q40629784-B8D6D584-A58F-4B3E-9D3A-E185D731FFEFQ40853145-453D3870-2BA6-4613-9C89-6CD7D5FDCA5BQ41607670-DF0C4F34-C02A-4AB6-8F09-039573D807E6Q41677197-01E74B87-EE33-4E88-89FB-8B13E4117FB8Q41708970-7F7B393D-E7CB-497F-B731-54D5530847E6Q47093606-15A55B7D-05FD-4262-BEF8-D23148F1E37CQ47438629-0747AEC0-3F80-4B39-ACDC-BF462BD0F07CQ47662798-2675BF26-0DB5-45B1-B275-FAC9638EF17FQ48294853-81B711A7-898D-4ED3-9E19-1B10B2F0261AQ49475238-FB049164-C1FD-4CDA-93B4-2AE5B7E6ABBFQ50043138-A35B23CE-F163-4E79-A990-5503E06FD1DBQ55053748-61046484-60A4-406C-8EAA-2C12A49F378DQ58710816-443E32F3-0430-4A84-A367-E3F7063FAD0BQ58805430-C9A8B245-E34B-4031-9EAC-8E5C5C9D2B70
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
RAS mutations in thyroid cancer
@ast
RAS mutations in thyroid cancer
@en
RAS mutations in thyroid cancer
@nl
type
label
RAS mutations in thyroid cancer
@ast
RAS mutations in thyroid cancer
@en
RAS mutations in thyroid cancer
@nl
prefLabel
RAS mutations in thyroid cancer
@ast
RAS mutations in thyroid cancer
@en
RAS mutations in thyroid cancer
@nl
P2093
P2860
P3181
P1433
P1476
RAS mutations in thyroid cancer
@en
P2093
P2860
P304
P3181
P356
10.1634/THEONCOLOGIST.2013-0072
P407
P577
2013-01-01T00:00:00Z